Pathogenica and Illumina have entered into an agreement to co-market a new version of the former’s HAI BioDetection kit in the Asia Pacific region.
Currently under development and compatible with Illumina's MiSeq benchtop sequencing system, HAI BioDetection kit is a research use only test to identify and sub-type bacterial species that are responsible for over 95% of hospital acquired infections.
Capable of identifying species such as A. baumannii, C. difficile, E. coli, K. pneumonia, P. aeruginosa, and S. aureus, the new kit provides sequence-level resolution with automated analysis software in a multiplexed assay that makes hospital-wide surveillance practical.
The solution can process 24-48 samples simultaneously per sequencing run and is able to bypass the requirement of bacterial isolation and culture, while increasing workflow.
Pathogenica CEO Yemi Adesokan said, "The introduction of an Illumina-compatible version of our kit emphasizes the platform-agnostic flexibility of our technology, and allows us to reach new users in the large number of clinical-facing facilities keen to use Illumina's sequencing technology."
The integrated solution will enable users to identify an expanded panel of bacteria and drug resistance genes present within clinical specimens and mixed cultures or isolates.
